MRGBP: A New Factor for Diagnosis and Prediction of Head and Neck Squamous Cell Carcinoma

Table 1

Correlation between MRGBP expression and clinicopathological characteristics of patients with HNSC.

Characteristic	Low expression of MRGBP	High expression of MRGBP
	251	251
Age, (%)			0.502
≤60	118 (23.6%)	127 (25.3%)
>60	132 (26.3%)	124 (24.8%)
Gender, (%)			0.003
Female	82 (16.3%)	52 (10.4%)
Male	169 (33.7%)	199 (39.6%)
Race, (%)			0.310
Asian	6 (1.2%)	4 (0.8%)
Black or African American	19 (3.9%)	28 (5.8%)
White	218 (44.9%)	210 (43.3%)
Smoker, (%)			0.026
No	67 (13.6%)	44 (8.9%)
Yes	182 (37%)	199 (40.4%)
Clinical stage, (%)			0.569
Stage I	12 (2.5%)	7 (1.4%)
Stage II	51 (10.5%)	44 (9%)
Stage III	49 (10%)	53 (10.9%)
Stage IV	134 (27.5%)	138 (28.3%)
T stage, (%)			0.069
T1	19 (3.9%)	14 (2.9%)
T2	82 (16.8%)	62 (12.7%)
T3	67 (13.8%)	64 (13.1%)
T4	77 (15.8%)	102 (20.9%)
N stage, (%)			0.124
N0	127 (26.5%)	112 (23.3%)
N1	35 (7.3%)	45 (9.4%)
N2	77 (16%)	77 (16%)
N3	1 (0.2%)	6 (1.2%)
M stage, (%)			0.373
M0	237 (49.7%)	235 (49.3%)
M1	4 (0.8%)	1 (0.2%)
Age, median (IQR)	61 (54, 69)	60 (52.5, 67)	0.174